Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Type 1 Diabetes Mellitus · Dehydration · HALO

HALOZYME THERAPEUTICS

HALOZYME THERAPEUTICS, INC.

HALOZYME THERAPEUTICS clinical programs — 45 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
12390 El Camino Real, San Diego, California 92130, US HQ
2021 Founded
530 Employees
Public company Type
HALO · NYSE Ticker
Company details
Status
Public
HQ
12390 El Camino Real, San Diego, California 92130, US
Founded
2021
Employees
530
Programs
45
Drugs
33
Patents
70
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

HALOZYME THERAPEUTICS projects

45 ClinicalTrials.gov programs sponsored by HALOZYME THERAPEUTICS.

HALOZYME THERAPEUTICS has 45 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

45 programs

Clinical programs

  1. Hylenex

    HALOZYME THERAPEUTICS, INC.

    Pain

    phase 3 small molecule completed

    1 trial

  2. Placebo

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Carcinoma

    phase 3 small molecule terminated

    1 trial

  3. Testosterone enanthate

    HALOZYME THERAPEUTICS, INC.

    Hypogonadism, Male

    phase 3 other active

    1 trial

  4. 5-Fluorouracil (5-FU)

    HALOZYME THERAPEUTICS, INC.

    Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

    phase 2 small molecule completed

    1 trial

  5. Atezolizumab

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  6. Axumin PET/CT

    HALOZYME THERAPEUTICS, INC.

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  7. CINRYZE with rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Hereditary Angioedema

    phase 2 mab completed

    1 trial

  8. Eribulin mesylate

    HALOZYME THERAPEUTICS, INC.

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  9. Gemcitabine

    HALOZYME THERAPEUTICS, INC.

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  10. Humalog

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  11. Humalog

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  12. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type II

    phase 2 small molecule completed

    1 trial

  13. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials

  14. Mitomycin C

    HALOZYME THERAPEUTICS, INC.

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  15. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  16. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  17. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Metastatic Pancreatic Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  18. Pegvorhyaluronidase alfa

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  19. rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Dermatitis, Allergic Contact

    phase 2 small molecule completed

    1 trial

  20. Chemophase

    HALOZYME THERAPEUTICS, INC.

    Superficial Bladder Cancer

    phase 1 small molecule completed

    1 trial

  21. Cohort 1: bococizumab 150 mg + rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Healthy

    phase 1 mab terminated

    1 trial

  22. Humalog

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  23. Insulin Lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  24. Insulin aspart

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  25. Ondansetron

    HALOZYME THERAPEUTICS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  26. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Solid Tumor

    phase 1 small molecule completed

    2 trials

  27. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Cholangiocarcinoma Non-resectable

    phase 1 small molecule terminated

    1 trial

  28. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    NSCLC

    phase 1 small molecule completed

    1 trial

  29. PEGylated recombinant human hyaluronidase PH20

    HALOZYME THERAPEUTICS, INC.

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  30. Recombinant human hyaluronidase PH20 (rHuPH20)

    HALOZYME THERAPEUTICS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  31. SC HYLENEX and Ceftriaxone

    HALOZYME THERAPEUTICS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  32. rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Risk Factors for or a Diagnosis of Osteoporosis

    phase 1 small molecule completed

    1 trial

  33. rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  34. 1838-009

    HALOZYME THERAPEUTICS, INC.

    Dehydration

    approved small molecule terminated

    1 trial

  35. Commercial Hylenex® recombinant (hyaluronidase human injection)

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    approved small molecule completed

    1 trial

  36. Hylenex

    HALOZYME THERAPEUTICS, INC.

    Healthy

    approved small molecule completed

    2 trials

  37. Isotonic hydration fluid and recombinant human hyaluronidase

    HALOZYME THERAPEUTICS, INC.

    Dehydration

    approved small molecule terminated

    1 trial

  38. Rapid Acting insulin with pre-treatment of rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    approved small molecule completed

    1 trial

  39. Sham Injection

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    approved small molecule completed

    1 trial

  40. hyaluronidase (human recombinant)/rehydration fluid

    HALOZYME THERAPEUTICS, INC.

    Dehydration

    approved small molecule completed

    1 trial

  41. hylenex-facilitated subcutaneous Lactated Ringer's infusion

    HALOZYME THERAPEUTICS, INC.

    Dehydration

    approved small molecule completed

    1 trial

  42. large protein molecule

    HALOZYME THERAPEUTICS, INC.

    Rheumatoid Arthritis

    approved small molecule completed

    1 trial

  43. recombinant human hyaluronidase

    HALOZYME THERAPEUTICS, INC.

    Healthy

    approved small molecule completed

    1 trial

  44. recombinant human hyaluronidase

    HALOZYME THERAPEUTICS, INC.

    Dehydration

    approved small molecule completed

    1 trial

  45. Gemcitabine

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Cancer

    small molecule active

    1 trial

Frequently asked questions

How many clinical projects does HALOZYME THERAPEUTICS have?

45 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.